Publication Name	World Journal of Hepatology
Manuscript ID	89394
Country	China

Received	2023-10-30 11:50
Peer-Review Started	2023-10-30 11:51
First Decision by Editorial Office Director	2023-11-22 23:33
Return for Revision	2023-11-22 23:33
Revised	2023-12-04 04:36
Publication Fee Transferred
Second Decision by Editor	2024-01-12 02:40
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2024-01-12 07:30
Articles in Press	2024-01-12 07:30
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-01-15 04:50
Publish the Manuscript Online	2024-01-23 09:31

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients
Manuscript Source	Unsolicited Manuscript
All Author List	Yu-Tong Sun and Qian-Qian Chen
ORCID	Author(s) ORCID Number Qian-Qian Chen http://orcid.org/0009-0006-9078-5711
Funding Agency and Grant Number
Corresponding Author	Qian-Qian Chen, MD, Associate Chief Physician, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100193, China. qian_qian_chen@163.com
Key Words	Tenofovir alafenamide; Entecavir; Serum lipid levels; Hepatitis B virus
Core Tip	With the significant increase in the incidence of nonalcoholic fatty liver disease (NAFLD) in China, the number of patients with co-morbid chronic hepatitis B (CHB) and NAFLD has gradually increased. This letter comments on a published study which showned that CHB patients treated with tenofovir alafenamide (TAF) had higher levels of total cholesterol than CHB patients treated with entecavir; however, TAF-induced dyslipidemia did not increase the incidence of NAFLD. We comment on the article.
Publish Date	2024-01-23 09:31
Citation	Sun YT, Chen QQ. Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients. World J Hepatol 2024; 16(1): 109-111
URL	https://www.wjgnet.com/1948-5182/full/v16/i1/109.htm
DOI	https://dx.doi.org/10.4254/wjh.v16.i1.109

Full Article (PDF)	WJH-16-109-with-cover.pdf
Full Article (Word)	WJH-16-109.docx
Manuscript File	89394_Auto_Edited-YJP.docx
Answering Reviewers	89394-Answering reviewers.pdf
Audio Core Tip	89394-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	89394-Conflict-of-interest statement.pdf
Copyright License Agreement	89394-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	89394-Language certificate.pdf
Peer-review Report	89394-Peer-review(s).pdf
Scientific Misconduct Check	89394-Bing-Qu XL-2.jpg
Scientific Editor Work List	89394-Scientific editor work list.pdf
CrossCheck Report	89394-CrossCheck report.pdf